Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab
Open Access
- 1 June 2018
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 45 (3) , 151-155
Abstract
No abstract availableKeywords
Funding Information
- HRB (104647)
- Wellcome Trust Senior Research Fellowship
- Cancer Research UK (C42738/A24868)
This publication has 14 references indexed in Scilit:
- Mechanisms of resistance to immune checkpoint inhibitorsBritish Journal of Cancer, 2018
- Cancer Immunotherapy Trials Underutilize Immune Response MonitoringThe Oncologist, 2017
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Connecting the Metabolic and Immune Responses to CancerTrends in Molecular Medicine, 2017
- Elements of cancer immunity and the cancer–immune set pointNature, 2017
- Familial Adrenocortical Carcinoma in Association With Lynch SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Toxicities of Immunotherapy for the PractitionerJournal of Clinical Oncology, 2015
- Adrenocortical Carcinoma Is a Lynch Syndrome–Associated CancerJournal of Clinical Oncology, 2013
- Combination Chemotherapy in Advanced Adrenocortical CarcinomaNew England Journal of Medicine, 2012